Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 4
1(25.0%)
4Total
Phase 2(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06992128Phase 2Recruiting

Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial

Role: collaborator

NCT04992026Phase 2Completed

The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer

Role: collaborator

NCT05594095Phase 2Recruiting

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Role: collaborator

NCT06078839Phase 4Not Yet Recruiting

Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy

Role: collaborator

All 4 trials loaded